Origin & tradition
Not traditional as an isolate: epicatechin is the main bioactive in dark chocolate and is also present in green tea and some fruits.
Western tradition · Flavonoid
The dark chocolate flavonoid linked to myostatin inhibition, cardiovascular protection, and mitochondrial biogenesis in human trials.
↑ iHerb link is an affiliate link — we may earn a commission at no cost to you.
Not traditional as an isolate: epicatechin is the main bioactive in dark chocolate and is also present in green tea and some fruits.
Key active: (-)-Epicatechin (flavan-3-ol from dark chocolate & green tea).
Epicatechin activates eNOS, promotes mitochondrial biogenesis via PGC-1α, and may inhibit myostatin (a muscle aging suppressor). Multiple small RCTs show cardiovascular benefits (blood pressure, endothelial function). Preclinical data suggests healthspan extension via SIRT1 and AMPK.
Effect summary
| Health outcome | Effect | Magnitude | Grade |
|---|---|---|---|
| Nitric oxide / endothelial function | Increases | Moderate | B |
| Myostatin levels | Decreases | Minor | C |
| Muscle protein synthesis markers | Increases | Minor | C |
| Cardiovascular markers (blood pressure, LDL) | Decreases | Minor | B |
Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data
Dosage guidance
Primary source is dark chocolate and green tea. Dark chocolate (85%+) provides meaningful amounts. High-dose isolated epicatechin studies show myostatin reduction and muscle effects, but most human data is at lower dietary intake levels.
Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.
Evidence summary
Human RCTs in cardiovascular/endothelial function; muscle aging data emerging
Epicatechin activates eNOS, promotes mitochondrial biogenesis via PGC-1α, and may inhibit myostatin (a muscle aging suppressor). Multiple small RCTs show cardiovascular benefits (blood pressure, endothelial function). Preclinical data suggests healthspan extension via SIRT1 and AMPK.
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-06-12. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Evidence collections
Compare the evidence
The mitochondrial electron carrier that declines with age and statin use — with cardiovascular trial support.
A mitochondrial cofactor active in both fat and water — the only antioxidant that regenerates glutathione, vitamin C, and vitamin E simultaneously.
A gut-derived metabolite that triggers mitophagy — with human trials on muscle and mitochondrial function.
The most potent known NRF2 activator, from broccoli, with human trials in cancer chemoprevention and neuroprotection.
Suppliers
Tell us what you need and we will source suppliers for you.